Clinical outcomes of patients (pts) age 80 or older treated with docetaxel (DOC) as first-line chemotherapy for castration-resistant prostate cancer (CRPC): Results of an Italian multicenter retrospective study (DELPHI study).

被引：2
|
作者：
Veccia, Antonello
Burgio, Salvatore Luca
Di Lorenzo, Giuseppe
Ortega, Cinzia
Scognamiglio, Florinda
Aieta, Michele
Zustovich, Fable
Mattioli, Rodolfo
Mansueto, Giovanni
Facchini, Gaetano
Procopio, Giuseppe
D'Angelo, Alessandro
Spizzo, Gilbert
Donini, Maddalena
Bortolus, Roberto
Vicario, Giovanni
Zucali, Paolo A.
Basso, Umberto
Lo Re, Giovanni
Caffo, Orazio
机构：
[1] Santa Chiara Hosp, Trento, Italy
[2] IRCCS Ist Sci Romagnolo Studio & Cura Tumori IRST, Meldola, Italy
[3] Univ Naples Federico II, GU Canc Sect, Naples, Italy
[4] Fdn Piemonte Oncol, Inst Canc Res & Treatment, Turin, Italy
[5] Cardarelli Hosp, Neaples, Italy
[6] IRCCS CROB Ctr Riferimento Oncol Basilicata, Rionero In Vulture, Italy
[7] Veneto Inst Oncol IRCCS, Padua, Italy
[8] Santa Croce Hosp, Med Oncol Unit, Fano Pu, Italy
[9] ASL Frosinone, Med Oncol Unit, Frosinone, Italy
[10] NCI Pascale Fdn, Neaples, Italy
[11] Fdn IRCCS Ist Nazl Tumori, Milan, Italy
[12] Civil Hosp, Taormina, Italy
[13] Civil Hosp, Merano, Italy
[14] Ist Ospitalieri Cremona, Cremona, Italy
[15] Natl Canc Ctr CRO, Aviano, Italy
[16] Osped San Giacomo Apostolo Med Oncol, Castelfranco Veneto, Italy
[17] Humanitas Canc Ctr, Rozzano, Italy
[18] Ist Oncol Veneto IOV IRCCS, Padua, Italy
[19] Santa Maria Angeli Gen Hosp, Pordenone, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 04期
关键词：
D O I：
10.1200/jco.2014.32.4_suppl.92
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
92
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Enzalutamide in patients with castration-resistant prostate cancer: retrospective, multicenter, real life study
    Gacci, Mauro
    Marchioni, Michele
    De Francesco, Piergustavo
    Natoli, Clara
    Calabro, Fabio
    Losanno, Tania
    Gianmartin, Cito
    Serni, Sergio
    Doni, Laura
    De Nunzio, Cosimo
    De Tursi, Michele
    Valeriani, Maurizio
    Giacinti, Silvana
    Alvarez-Maestro, Mario
    Scarcia, Marcello
    Ludovico, Giuseppe M.
    Del Bene, Gabriella
    Simone, Giuseppe
    Ferriero, Mariaconsiglia
    Tuderti, Gabriele
    Bove, Pierluigi
    Laudisi, Anastasia
    Carrieri, Giuseppe
    Cormio, Luigi
    Verze, Paolo
    La Rocca, Roberto
    Falsaperla, Mario
    Frantellizzi, Viviana
    Greco, Francesco
    Di Nicola, Marta
    Schips, Luigi
    Cindolo, Luca
    MINERVA UROLOGY AND NEPHROLOGY, 2021, 73 (04): : 489 - 497
  • [42] Patient Preference Between Cabazitaxel and Docetaxel for First-line Chemotherapy in Metastatic Castration-resistant Prostate Cancer: The CABADOC Trial
    Baciarello, Giulia
    Delva, Remy
    Gravis, Gwenaelle
    Tazi, Youssef
    Beuzeboc, Philippe
    Gross-Goupil, Marine
    Bompas, Emmanuelle
    Joly, Florence
    Greilsamer, Charlotte
    Hon, Thierry Nguyen Tan
    Barthelemy, Philippe
    Culine, Stephane
    Berdah, Jean Francois
    Deblock, Mathilde
    Ratta, Raffaele
    Flechon, Aude
    Cheneau, Caroline
    Maillard, Aline
    Martineau, Geraldine
    Borget, Isabelle
    Fizazi, Karim
    EUROPEAN UROLOGY, 2022, 81 (03) : 234 - 240
  • [43] Clinical outcomes and toxicity of estramustine phosphate (EP) addition to docetaxel (D) as first-line therapy for castration-resistant prostate cancer (CRPC): A cumulative analysis on 243 patients (pts) from two randomized phase II trials
    Caffo, Orazio
    Sava, Teodoro
    Zustovich, Fable
    Lodde, Michele
    Sacco, Cosimo
    Lo Re, Giovanni
    Buti, Sebastiano
    Basso, Umberto
    Gamucci, Teresa
    Facchini, Gaetano
    Perin, Alessandra
    Segati, Romana
    Russo, Lucianna
    Veccia, Antonello
    Galligioni, Enzo
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [44] Intermittent docetaxel chemotherapy as first-line treatment for metastatic castration-resistant prostate cancer patients (vol 11, pg 965, 2015)
    Caffo, Orazio
    Lo Re, Giovanni
    Sava, Teodoro
    Buti, Sebastiano
    Sacco, Cosimo
    Basso, Umberto
    Zustovich, Fable
    Lodde, Michele
    Perin, Alessandra
    Facchini, Gaetano
    Veccia, Antonello
    Maines, Francesca
    Barile, Carmen
    Fratino, Lucia
    Gernone, Angela
    De Vivo, Rocco
    Pappagallo, Giovanni L.
    Galligioni, Enzo
    FUTURE ONCOLOGY, 2015, 11 (12) : 1845 - 1845
  • [45] Docetaxel Rechallenge Improves Survival in Patients With Metastatic Castration-resistant Prostate Cancer: A Retrospective Study
    Hung, Sheng-Chun
    Chang, Li-Wen
    Li, Jian-Ri
    Wang, Shian-Shiang
    Yang, Cheng-Kuang
    Chen, Chuan-Shu
    Lu, Kevin
    Chen, Cheng-Che
    Wang, Shu-Chi
    Lin, Chia-Yen
    Chen-Li Cheng
    Ou, Yen-Chuan
    Chiu, Kun-Yuan
    IN VIVO, 2021, 35 (06): : 3509 - 3519
  • [46] CLINICAL OUTCOMES BY RELATIVE DOCETAXEL DOSE AND DOSE INTENSITY AS CHEMOTHERAPY WITH CASTRATION-RESISTANT PROSTATE CANCER: A RETROSPECTIVE MULTI-INSTITUTIONAL COLLABORATIVE STUDY
    Kamiya, Naoto
    Suzuki, Hiroyoshi
    Ueda, Takeshi
    Nakatsu, Hiroomi
    Sato, Naohide
    Mikami, Kazuo
    Sato, Nobuo
    Ichikawa, Tomohiko
    JOURNAL OF UROLOGY, 2013, 189 (04): : E315 - E316
  • [47] Multicenter randomized phase II study comparing docetaxel plus curcumin versus docetaxel plus placebo in first-line treatment of metastatic castration-resistant prostate cancer
    Passildas-Jahanmohan, Judith
    Eymard, Jean-Christophe
    Pouget, Melanie
    Kwiatkowski, Fabrice
    Van Praagh, Isabelle
    Savareux, Laurent
    Atger, Marc
    Durando, Xavier
    Abrial, Catherine
    Richard, Damien
    Ginzac Couve, Angeline
    Thivat, Emilie
    Monange, Brigitte
    Chollet, Philippe
    Mahammedi, Hakim
    CANCER MEDICINE, 2021, 10 (07): : 2332 - 2340
  • [48] A multicentric phase II randomized trial of docetaxel (D) plus enzalutamide (E) versus docetaxel (D) as first-line chemotherapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): CHEIRON study.
    Caffo, Orazio
    Palesandro, Erica
    Nole, Franco
    Gasparro, Donatello
    Mucciarini, Claudia
    Aieta, Michele
    Zagonel, Vittorina
    Iacovelli, Roberto
    De Giorgi, Ugo
    Rossetti, Sabrina
    Fratino, Lucia
    Sacco, Cosimo
    Nicodemo, Maurizio
    Giordano, Monica
    Sartori, Donata
    Scapoli, Daniela
    Verri, Elena
    Kinspergher, Stefania
    Pappagallo, Giovanni L.
    Aglietta, Massimo
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [49] Clinical outcomes by relative docetaxel dose and dose intensity as chemotherapy for Japanese patients with castration-resistant prostate cancer: a retrospective multi-institutional collaborative study
    Kamiya, Naoto
    Suzuki, Hiroyoshi
    Ueda, Takeshi
    Sato, Naohide
    Nakatsu, Hiroomi
    Mikami, Kazuo
    Sato, Nobuo
    Nomura, Kazushi
    Akakura, Koichiro
    Okano, Tatsuya
    Ooki, Takemasa
    Naya, Yukio
    Ota, Sho
    Masai, Motoyuki
    Ichikawa, Tomohiko
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2014, 19 (01) : 157 - 164
  • [50] Clinical outcomes by relative docetaxel dose and dose intensity as chemotherapy for Japanese patients with castration-resistant prostate cancer: a retrospective multi-institutional collaborative study
    Naoto Kamiya
    Hiroyoshi Suzuki
    Takeshi Ueda
    Naohide Sato
    Hiroomi Nakatsu
    Kazuo Mikami
    Nobuo Sato
    Kazushi Nomura
    Koichiro Akakura
    Tatsuya Okano
    Takemasa Ooki
    Yukio Naya
    Sho Ota
    Motoyuki Masai
    Tomohiko Ichikawa
    International Journal of Clinical Oncology, 2014, 19 : 157 - 164
12345